Patents by Inventor Jennifer E. Adair

Jennifer E. Adair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND ENGINEERED NANOPARTICLES TO PROVIDE TARGETED GENETIC THERAPIES
    Publication number: 20230279441
    Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.
    Type: Application
    Filed: December 8, 2022
    Publication date: September 7, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Jennifer E. Adair, Reza Shahbazi
  • STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL
    Publication number: 20230159895
    Abstract: Strategies to assess and/or produce cell populations with predictive engraftment potential are described. The cell populations can be used for a variety of therapeutic and research purposes.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Stefan Radtke, Hans-Peter Kiem, Jennifer E. Adair
  • Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
    Patent number: 11603544
    Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: March 14, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Jennifer E. Adair, Reza Shahbazi
  • REDUCED AND MINIMAL MANIPULATION MANUFACTURING OF GENETICALLY-MODIFIED CELLS
    Publication number: 20220025403
    Abstract: Nanoparticles to genetically modify selected cell types within a biological sample that has been subjected to reduced or minimal manipulation are described. The nanoparticles deliver all components required for precise genome engineering and overcome numerous drawbacks associated with current clinical practices to genetically engineer cells for therapeutic purposes.
    Type: Application
    Filed: December 5, 2019
    Publication date: January 27, 2022
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Reza Shahbazi
  • GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND ENGINEERED NANOPARTICLES TO PROVIDE TARGETED GENETIC THERAPIES
    Publication number: 20210171983
    Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 10, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Jennifer E. Adair, Reza Shahbazi
  • POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY
    Publication number: 20210052658
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Application
    Filed: July 7, 2020
    Publication date: February 25, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Point-of-care and/or portable platform for gene therapy
    Patent number: 10828333
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 10, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • THERAPEUTIC FORMULATIONS CONTAINING CD34+ STEM CELLS DERIVED FROM NEGATIVE SELECTION
    Publication number: 20200199534
    Abstract: Therapeutic formulations containing CD34+ stem cells derived from negative selection are described. The cells within the formulations can be genetically-modified for a number of therapeutic purposes. The disclosure is particularly useful for the treatment of patients with fragile stem cells or stem cells with low CD34+ expression levels.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • IN VIVO GENE THERAPY FOR IMMUNE DEFICIENCIES
    Publication number: 20200009266
    Abstract: In vivo gene therapies for immune deficiencies are described. The in vivo gene therapies utilize a foamy viral vector including a PGK promoter with a therapeutic gene. The foamy viral vector can be beneficially administered with cell mobilization into the peripheral blood.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 9, 2020
    Applicants: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Frieda Chan, Olivier Humbert, Hans-Peter Kiem, Jennifer E. Adair, David Rawlings, Andrew Scharenberg, Troy Torgerson
  • POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY
    Publication number: 20190365817
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 5, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL
    Publication number: 20190345450
    Abstract: Strategies to assess and/or produce cell populations with predictive engraftment potential are described. The cell populations can be used for a variety of therapeutic and research purposes.
    Type: Application
    Filed: June 16, 2017
    Publication date: November 14, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Stefan Radtke, Hans-Peter Kiem, Jennifer E. Adair
  • Point-of-care and/or portable platform for gene therapy
    Patent number: 10350245
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: July 16, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY
    Publication number: 20180169148
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Application
    Filed: January 21, 2016
    Publication date: June 21, 2018
    Inventors: Jennifer E. Adair, Hans-Peter Kiem